In short
Cobimetinib is an investigational drug being studied in clinical trials for its potential to treat a variety of medical conditions. This article summarizes key information about ongoing clinical trials using cobimetinib, including its applications, dosing, and preliminary findings. The trials are exploring cobimetinib's efficacy and safety in treating conditions such as histiocytic disorders, arteriovenous malformations, rare tumors, and certain types of cancer.
At a glance
- Drug Name
- Cobimetinib (also known as GDC-0973, XL518, Cotellic)
- Mechanism of Action
- MEK inhibitor, blocks cell growth signaling
- Administration
- Oral (tablets or suspension)
- Common Dosing Schedule
- 21 days on, 7 days off in 28-day cycles
- Conditions Studied
- Histiocytic disorders, Langerhans cell histiocytosis, arteriovenous malformations, rare tumors, chronic myelomonocytic leukemia, various cancers
- Primary Outcomes Measured
- Overall response rate, progression-free survival, safety, tolerability, pharmacokinetics
- Trial Phases
- Phase I, II, and Ib studies
- Combination Therapies
- Some trials combine cobimetinib with other drugs like atezolizumab, vemurafenib, or onartuzumab
What is Cobimetinib?
Cobimetinib is a medication used in the treatment of various cancers and other medical conditions. It's also known by several other names, including Cotellic, GDC-0973, RO5514041, and XL518. This drug belongs to a class of medications called MEK inhibitors, which work by blocking certain proteins involved in cancer cell growth.
How Cobimetinib Works
Cobimetinib works by targeting a specific protein called MEK (Mitogen-activated protein kinase). In many cancers, especially those with a mutation in a gene called BRAF, the MEK protein is overactive, leading to uncontrolled cell growth. By inhibiting MEK, cobimetinib helps to slow down or stop the growth of cancer cells.
In some cases, cobimetinib is used in combination with other drugs, particularly vemurafenib, which targets the BRAF protein. This combination therapy can be more effective in treating certain types of cancer, such as melanoma with a BRAF V600 mutation.
Conditions Treated with Cobimetinib
Cobimetinib is used to treat various conditions, including:
- Malignant Melanoma: A type of skin cancer, particularly when it has spread to other parts of the body (metastatic) and has a specific genetic mutation called BRAF V600.
- Histiocytic Disorders: A group of rare diseases that involve an overgrowth of certain types of immune cells.
- Langerhans Cell Histiocytosis (LCH): A rare disorder where certain immune cells build up in various organs.
- Erdheim-Chester Disease: A rare form of non-Langerhans cell histiocytosis.
- Arteriovenous Malformations: Abnormal connections between arteries and veins.
- Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer.
How Cobimetinib is Administered
Cobimetinib is typically taken orally in the form of tablets or a liquid suspension. The dosage and schedule can vary depending on the condition being treated and the patient's individual needs. Common dosing schedules include:
- 60 mg once daily for 21 days, followed by a 7-day break (28-day cycle).
- 60 mg once daily for 28 days continuously.
Your doctor will determine the best dosing schedule for your specific situation. It's important to take cobimetinib exactly as prescribed and to inform your healthcare provider of any side effects you experience.
Potential Side Effects
Like all medications, cobimetinib can cause side effects. Some of the most common side effects include:
- Diarrhea
- Nausea and vomiting
- Rash or skin reactions
- Fatigue
- Fever
- Changes in liver function tests
- Vision problems
More serious side effects can occur, although they are less common. These may include heart problems, severe skin reactions, and eye problems. It's crucial to report any side effects to your healthcare provider promptly.
Ongoing Research and Future Potential
Researchers continue to study cobimetinib for its potential in treating various conditions. Some areas of ongoing research include:
- Combination therapy with other drugs for different types of cancer.
- Treatment of rare diseases like histiocytic disorders.
- Use in pediatric patients with solid tumors.
- Treatment of arteriovenous malformations.
These ongoing studies aim to expand our understanding of how cobimetinib can be used effectively and safely in various medical conditions.